322 related articles for article (PubMed ID: 18544432)
21. Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII.
Tokgoz H; Caliskan U; Lavigne-Lissalde G; Giansily-Blaizot M
Haemophilia; 2012 Jan; 18(1):e25-7. PubMed ID: 21973016
[No Abstract] [Full Text] [Related]
22. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S111-4. PubMed ID: 9819040
[TBL] [Abstract][Full Text] [Related]
23. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.
Napolitano M; Di Minno MN; Batorova A; Dolce A; Giansily-Blaizot M; Ingerslev J; Schved JF; Auerswald G; Kenet G; Karimi M; Shamsi T; Ruiz de Sáez A; Dolatkhah R; Chuansumrit A; Bertrand MA; Mariani G
Haemophilia; 2016 Sep; 22(5):752-9. PubMed ID: 27338009
[TBL] [Abstract][Full Text] [Related]
24. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
25. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Tcheng WY; Donkin J; Konzal S; Wong WY
Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
[TBL] [Abstract][Full Text] [Related]
26. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
27. Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots.
Désage S; Chamouard V; Meunier S; Enjolras N; Sobas F; Négrier C; Le Quellec S
Haemophilia; 2021 Jul; 27(4):e487-e490. PubMed ID: 33215792
[No Abstract] [Full Text] [Related]
28. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.
Berrettini M; Mariani G; Schiavoni M; Rocino A; Di Paolantonio T; Longo G; Morfini M
Haematologica; 2001 Jun; 86(6):640-5. PubMed ID: 11418374
[TBL] [Abstract][Full Text] [Related]
29. Recurrent intracranial haemorrhages in a patient with factor seven deficiency: a case report.
Fadzil F
Med J Malaysia; 2011 Aug; 66(3):261-3. PubMed ID: 22111455
[TBL] [Abstract][Full Text] [Related]
30. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Mariani G; Konkle BA; Ingerslev J
Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
[TBL] [Abstract][Full Text] [Related]
31. On-label versus off-label use of recombinant activated factor VII: a comprehensive review of use in two Canadian centers.
Carcao MD; Webert KE
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S68-71. PubMed ID: 18544429
[TBL] [Abstract][Full Text] [Related]
32. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive review of rFVIIa use in a tertiary care pediatric center.
Heller M; Lau W; Pazmino-Canizares J; Brandão LR; Carcao M
Pediatr Blood Cancer; 2008 May; 50(5):1013-7. PubMed ID: 17960639
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients.
van Geffen M; Mathijssen NC; Holme PA; Laros-van Gorkom BA; van Kraaij MG; Masereeuw R; Peyvandi F; van Heerde WL
Thromb Res; 2013 Jul; 132(1):116-22. PubMed ID: 23731565
[TBL] [Abstract][Full Text] [Related]
35. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
[TBL] [Abstract][Full Text] [Related]
36. A new perspective on perioperative coagulation management in a patient with congenital factor VII deficiency: A case report.
Sun Y; Jia L; Yang Z; Chen W
Medicine (Baltimore); 2018 Nov; 97(44):e12776. PubMed ID: 30383632
[TBL] [Abstract][Full Text] [Related]
37. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant.
Cetin H; Yalaz M; Akisu M; Karapinar DY; Kavakli K; Kultursay N
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):213-6. PubMed ID: 16575260
[TBL] [Abstract][Full Text] [Related]
38. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
39. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
40. Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients.
Felfernig M; Huepfl M
Clin Neurol Neurosurg; 2008 Mar; 110(3):227-32. PubMed ID: 18083302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
